Ginkgo Bioworks Holdings Future Growth
Future criteria checks 1/6
Ginkgo Bioworks Holdings is forecast to grow earnings and revenue by 22.4% and 18.3% per annum respectively. EPS is expected to grow by 25% per annum. Return on equity is forecast to be -124.8% in 3 years.
Key information
22.4%
Earnings growth rate
25.0%
EPS growth rate
| Chemicals earnings growth | 15.2% |
| Revenue growth rate | 18.3% |
| Future return on equity | -124.8% |
| Analyst coverage | Good |
| Last updated | 17 Apr 2024 |
Recent future growth updates
Recent updates
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06
With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Ginkgo Bioworks: Avoid For Now
Feb 20Ginkgo: Standardizing Offerings For Growth
Feb 08Ginkgo Bioworks: Increasing Focus On Pharma And Biotech
Jan 12Ginkgo Bioworks launches Ginkgo Enzyme Services
Dec 08Ginkgo, Lygos team up to produce sustainable biobased specialty chemicals
Nov 11Ginkgo, Draper develop new technologies to detect engineered DNA
Oct 17Ginkgo stock rises on acquisition of French biotech Altar
Oct 04Ginkgo Bioworks: Promising Upside But Not Without Risks
Sep 28Ginkgo Bioworks: May The Ginkgo King Grow
Sep 13Is There An Opportunity With Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 50% Undervaluation?
Aug 26Gingko Bioworks: Near-Term Challenges Trump Downstream Economics
Aug 17Ginkgo Bioworks: Time To Buy
Aug 10Biotech Zymergen surges 21% on $300M buyout deal with Ginkgo
Jul 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 423 | -410 | N/A | N/A | 3 |
| 12/31/2025 | 310 | -534 | N/A | N/A | 7 |
| 12/31/2024 | 223 | -631 | N/A | N/A | 7 |
| 12/31/2023 | 251 | -893 | -336 | -295 | N/A |
| 9/30/2023 | 315 | -857 | -405 | -342 | N/A |
| 6/30/2023 | 326 | -1,224 | -369 | -297 | N/A |
| 3/31/2023 | 390 | -1,719 | -391 | -323 | N/A |
| 12/31/2022 | 478 | -2,105 | -304 | -252 | N/A |
| 9/30/2022 | 528 | -3,530 | -345 | -313 | N/A |
| 6/30/2022 | 539 | -2,962 | -314 | -290 | N/A |
| 3/31/2022 | 438 | -2,347 | -264 | -226 | N/A |
| 12/31/2021 | 314 | -1,830 | -310 | -254 | N/A |
| 9/30/2021 | 197 | -276 | -218 | -148 | N/A |
| 6/30/2021 | 133 | -200 | -262 | -168 | N/A |
| 3/31/2021 | 100 | -175 | -236 | -160 | N/A |
| 12/31/2020 | 77 | -127 | -194 | -136 | N/A |
| 12/31/2019 | 54 | -119 | -67 | -45 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DNA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DNA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DNA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DNA's revenue (18.3% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: DNA's revenue (18.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DNA is forecast to be unprofitable in 3 years.